Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $500000.0.

  • Zentalis Pharmaceuticals' Other Non-Current Liabilities fell 4979.92% to $500000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $500000.0, marking a year-over-year decrease of 4979.92%. This contributed to the annual value of $849000.0 for FY2024, which is 5230.34% down from last year.
  • Latest data reveals that Zentalis Pharmaceuticals reported Other Non-Current Liabilities of $500000.0 as of Q3 2025, which was down 4979.92% from $500000.0 recorded in Q2 2025.
  • Zentalis Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $45.0 million during Q1 2022, with a 5-year trough of $500000.0 in Q2 2025.
  • For the 4-year period, Zentalis Pharmaceuticals' Other Non-Current Liabilities averaged around $4.7 million, with its median value being $1.3 million (2024).
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 9601.58% in 2023, then tumbled by 2779.02% in 2024.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Other Non-Current Liabilities stood at $2.6 million in 2022, then tumbled by 32.06% to $1.8 million in 2023, then tumbled by 52.3% to $849000.0 in 2024, then plummeted by 41.11% to $500000.0 in 2025.
  • Its Other Non-Current Liabilities stands at $500000.0 for Q3 2025, versus $500000.0 for Q2 2025 and $558000.0 for Q1 2025.